Table 3.
PET majority, AD and mCERADSOT assessment by disease category
| Disease category | Number | Percent | PETmaj abnormal | # With coincident ADa | # mCERADSOT abnormal |
|---|---|---|---|---|---|
| Alzheimer's Diseasea | 66 | (62%) | 62 | 66 | 64 |
| Lewy Body Diseaseb | 29 | (27%) | 23 | 16 | 22 |
| Cerebral Amyloid Angiopathyc | 27 | (25%) | 23 | 24 | 25 |
| Vasculard | 21 | (20%) | 14 | 14 | 16 |
| Arteriosclerosise | 13 | (12%) | 9 | 9 | 11 |
| Infarct | 7 | (7%) | 3 | 2 | 3 |
| Normal | 6 | (6%) | 0 | 0 | 0 |
| Ageing Changes | 3 | (3%) | 0 | 0 | 0 |
| TDP43 immunopositivef | 3 | (3%) | 0 | 0 | 2 |
| Tangle predominant dementia | 2 | (2%) | 0 | 0 | 0 |
| Progressive Supranuclear Palsy | 2 | (2%) | 0 | 0 | 0 |
| Atherosclerosis | 2 | (2%) | 1 | 2 | 2 |
| Frontotemporal Dementia | 1 | (1%) | 0 | 0 | 0 |
| Metastatic carcinoma | 1 | (1%) | 1 | 1 | 1 |
| Hydrocephalus | 1 | (1%) | 1 | 1 | 1 |
| Multiple system atrophy | 1 | (1%) | 1 | 0 | 1 |
| Neurofibrillary degeneration | 1 | (1%) | 0 | 0 | 1 |
| Parkinson's Disease | 1 | (1%) | 0 | 0 | 0 |
AD Alzheimer’s disease, mCERAD SOT standard of truth by modified Consortium to Establish a Registry for Alzheimer’s Disease criteria, N Number of subjects, PETmaj majority read of positron emission tomography images, SOT standard of truth
All neuropathology diagnoses made blind to clinical data
aIncludes intermediate or high likelihood by National Institute of Ageing-Reagan Institute criteria irrespective of dementia status
bDiagnosed as dementia with Lewy bodies blinded to clinical data
cDoes not include focal cerebral amyloid angiopathy
dIncludes: multifocal infarcts, microinfarcts, cerebral vascular disease, vascular brain injury and vascular dementia
eincludes arteriosclerosis and arteriolosclerosis
fTDP43 immunopositivity was recorded at the site neuropathology laboratories, not as part of the diagnoses for the GE studies. This analysis was not performed on all subjects